- KeyBanc analyst Michael Turits downgraded WalkMe Ltd (NASDAQ:WKME) to Sector Weight from Overweight without a price target.
- The re-rating followed a modest first-quarter revenue beat, but an ARR miss, decline in quarterly enterprise DBNRR, slowing RPO growth, and -3% second-quarter revenue guide miss on slipped large deals in Q1.
- WalkMe maintained the 2022 revenue guide despite the Q2 miss.
- Encouragingly, the management indicated pushouts were expansions with existing 7-figure customers, delayed by the need to work with procurement and by pricing discussion as they move up the market, with some already closed in a solid Q2 start.
- While Turits view WKME’s DAP as providing attractive enterprise ROI, the pushouts underscore DAP’s still evangelical sale and steeper risks than for core front/back office software given inflation/potential recession.
- Turits was also more cautious on CF losses.
- Turits looked for sustained operating leverage and stabilization of ample deal visibility to return to a more constructive stance on the stock and look to analyst day for more details.
- Price Action: WKME shares traded lower by 27.8% at $8.81 on the last check Tuesday.
Tandem Diabetes Care Announces Presentations Demonstrating ‘Immediate And Sustained Real-World Improvements With Control-IQ Technology’
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim X2™ insulin pump with Control-IQ™
